Richard Pzena’s Takeda Pharmaceutical TAK Stock Holding History

Richard Pzena’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$606K	Buy	37,820 +9,460	+33%	+$157K	﹤0.01%	142
2026 Q1	$525K	Buy	28,360 +7,733	+37%	+$136K	﹤0.01%	144
2025 Q4	$322K	Buy	+20,627	New	+$295K	﹤0.01%	146

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Richard Pzena's TAK Position: Q2 2026 in Review

Richard Pzena increased its Takeda Pharmaceutical (TAK) stake by 33% in Q2 2026, buying an estimated $157K and bringing the position to 37,820 shares worth $606K. The position accounts for ﹤0.01% of the portfolio, ranked #142.

Richard Pzena first reported a position in TAK in Q4 2025 and has held it in 3 quarters since. 375 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Richard Pzena held 37,820 shares of Takeda Pharmaceutical worth $606K as of Q2 2026.
Richard Pzena bought 9,460 Takeda Pharmaceutical shares in Q2 2026, an estimated $157K.
Takeda Pharmaceutical made up ﹤0.01% of Richard Pzena's portfolio in Q2 2026, its #142 holding.
Richard Pzena first reported a position in Takeda Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
375 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Pzena Investment Management's 13F filing for Q2 2026, filed 7 Aug 2026.